PHAT

Phathom Pharmaceuticals, Inc.

Fundamental data last updated:September 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

 


Analyze PHAT on TradingView

VALUATION

P/E

-5.38

Market Cap ($M USD)

$823.08M

Forward P/E

2.19

PEG

0.01

PRICE TO SALES

4.02

PRICE TO BOOK

-2.51

EV / EBITDA

-6.71

5-Year Average P/E

Free Cash Flow Yield

-11.83%

DCF Value

$-6.31

Graham Number

N/A

Price to FCF

-8.45

EV to FCF

-6.62

Earnings Yield

-18.58%

FCF Yield

-11.83%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.92

Next Year EPS Growth Estimate

$4.71

Next Year Revenue Growth Estimate

$1.02B

Return on Equity (ROE)

39.24%

FREE CASH FLOW

Operating Margin

-47.15%

Debt-to-Equity

-0.01

Piotroski F-Score

3

Altman Z-Score

-5.96

Return on Invested Capital (ROIC)

-53.64%

Current Ratio

2.21

Quick Ratio

2.16

Net Debt to EBITDA

1.86

Interest Coverage

-1.47

Gross Profit margin

84.93%

FCF PER SHARE

$-1.19

REVENUE PER SHARE

$2.50

Analyze PHAT on TradingView

Gainseekers Quantitative Analysis

Summary

The market appears to be mispricing Phathom Pharmaceuticals, Inc., with its snapshot price trading significantly below its DCF value. The Forward P/E of 2.58 suggests expectations of robust future earnings, yet the negative Altman Z-score of -5.82 raises red flags about financial distress. The Earnings Yield is deeply negative, indicating that the company is not currently generating positive earnings relative to its price. Despite these concerns, the market cap of nearly $970 million reflects a degree of investor confidence, possibly driven by anticipated earnings growth.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Phathom Pharmaceuticals is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology aligns with AI-driven innovations, potentially enhancing R&D efficiency. However, execution will be key to translating tech potential into tangible results.

The Bull Case

For the value or GARP investor, Phathom Pharmaceuticals presents an intriguing opportunity. The Forward PEG ratio of 0.0075 is exceptionally low, indicating potential undervaluation relative to growth. Despite a negative FCF Yield, the company's ROIC of -53.64% suggests room for improvement in capital efficiency. The Piotroski F-Score of 3 signals some financial health concerns, yet the gross profit margin of 84.93% highlights strong pricing power.

The Bear Case

Phathom Pharmaceuticals faces significant structural risks, primarily due to its negative operating margin of -47.15% and a deeply negative Price to FCF ratio. The Altman Z-score indicates potential financial distress, and the negative EV to EBITDA ratio further underscores operational challenges. While the company is not over-leveraged, its inability to cover interest expenses is concerning. The stock's distance from its 52-week high suggests limited upside potential in the near term.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$24.67

Institutional Ownership %

1-Year Beta

0.57

Insider Buying % (6 Mo)

Distance to 52-Week High

77.42%

Distance to 52-Week Low

60.76%

EARNINGS SURPRISE %

-37.04%

50-DAY SMA

$11.76

200-DAY SMA

$12.85

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.